Zymeworks Inc.(ZYME)

Sector:

Healthcare

Description:

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It is also advancing a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Current Price

$8.67

RSI

51.90

Market Capitalization:

496M

Beta:

1.11

Volume:

211,789

Analyst Target Price:

$ 12.31

Economiic Fair Price:


November 08, 2022
August 04, 2022
Q2
N/A
N/A
N/A
N/A
N/A
198.6M
32M
-4.969
N/A
0.485
-0.978

16347.72 %
-7158983.47 %
-67.82 %
147.82 %
23.30 %
-12.32 %

$ 34M
87234.17 %
$ 39K
-99.87 %
$ 29.5M
-44.28 %
$ 53M
2.43 %
$ 51.8M
370.18 %
$ 11M

$ -262.3M
-30.47 %
$ -201.1M
-110.02 %
$ -95.7M
-561.20 %
$ 20.8M
815.27 %
$ -2.9M
92.87 %
$ -40.7M

$ -270.8M
-150220.60 %
$ -180.1K
99.88 %
$ -146M
-324.66 %
$ -34.4M
-245.16 %
$ -10M
74.38 %
$ -38.9M

News

Press Releases

Notable Dates